Ingrid Eliasson leads the Life Sciences practice group. She works primarily with regulatory and commercial issues in the pharmaceutical and medtech sectors. Her practice within the Life Sciences sector includes regulatory issues, compliance audits, pharma distribution agreements, clinical trials, CRO agreements, cooperation between pharma companies and Swedish healthcare, reimbursement and pricing models, data protection and anti-corruption issues.

Ingrid has been legal advisor to the Swedish innovative pharma association throughout the re-modelling of the Swedish pharmacy and distribution markets which started 2009 and is still on-going, and has a wide experience of contacts with Swedish authorities in the Life Sciences sector.